Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
boston blog main
deals
6
×
life sciences
national blog main
san francisco blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alzheimer's disease
cancer
cancer immunotherapy
clinical trials
gilead sciences
merck
novartis
astrazeneca
biogen
crispr
What
bio
roundup
drug
acquisitions
ceo
biggest
companies
daniel
gilead
medicines
nash
news
o’day
sciences
treatment
abbvie
albert
alliance
announced
approval
approved
biogen’s
biopharmaceutical
biotech
bourla
build
buy
collabs
company
company’s
convo
covid
crispr
deal
debut
digital
disease
dyne’s
earlier
editas
Language
unset
unknown
Current search:
abbvie
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More